Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Nina, Keldsen"'
Autor:
Mogens K Boisen, Christian Dehlendorff, Dorte Linnemann, Boye S Nielsen, Jim S Larsen, Kell Osterlind, Svend E Nielsen, Line S Tarpgaard, Camilla Qvortrup, Per Pfeiffer, Niels H Holländer, Nina Keldsen, Torben F Hansen, Brita B Jensen, Estrid V S Høgdall, Benny V Jensen, Julia S Johansen
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109430 (2014)
PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN
Externí odkaz:
https://doaj.org/article/6cd8372b3db94d9ebca0c391d81dd6a1
Publikováno v:
Current drug safety. 11(3)
Background: Forty-seven cases (38 men and 9 women) of pulmonary toxicity caused by oxaliplatin have previously been published, but the issue has not been investigated in a prospective setting. Our purpose was to assess how oxaliplatin affects the pul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648e983ae2ca0e461e00f0cc74b86c85
https://pubmed.ncbi.nlm.nih.gov/27117288
https://pubmed.ncbi.nlm.nih.gov/27117288
Autor:
Kjell Magne Tveit, Anders Johnsson, Bengt Glimelius, Eva Hofsli, Seppo Pyrhönen, Fridbjorn Sigurdsson, Halfdan Sorbye, Elin H. Kure, Elke Birkemeyer, Tone Ikdahl, Nina Keldsen, Hans Starkhammar, Mette Karen Yilmaz, Per Pfeiffer, Tone Fokstuen, Eva Skovlund, Anne Berit Erdal, Tormod Kyrre Guren, Flemming Hansen, Olav Dajani, Thoralf Christoffersen, Olav Dahl
Publikováno v:
Tveit, K M, Guren, T, Glimelius, B, Pfeiffer, P, Sorbye, H, Pyrhonen, S, Sigurdsson, F, Kure, E, Ikdahl, T, Skovlund, E, Fokstuen, T, Hansen, F, Hofsli, E, Birkemeyer, E, Johnsson, A, Starkhammar, H, Yilmaz, M K, Keldsen, N, Erdal, A B, Dajani, O, Dahl, O & Christoffersen, T 2012, ' Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer : The NORDIC-VII Study ', Journal of Clinical Oncology, vol. 30, no. 15, pp. 1755-62 . https://doi.org/10.1200/JCO.2011.38.0915
Tveit, K M, Guren, T, Glimelius, B, Pfeiffer, P, Sorbye, H, Pyrhonen, S, Sigurdsson, F, Kure, E, Ikdahl, T, Skovlund, E, Fokstuen, T, Hansen, F, Hofsli, E, Birkemeyer, E, Johnsson, A, Starkhammar, H, Yilmaz, M K, Keldsen, N, Erdal, A B, Dajani, O, Dahl, O & Christoffersen, T 2012, ' Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer : the NORDIC-VII study ', Journal of Clinical Oncology, vol. 30, no. 15, pp. 1755-1762 . https://doi.org/10.1200/JCO.2011.38.0915
Tveit, K M, Guren, T, Glimelius, B, Pfeiffer, P, Sorbye, H, Pyrhonen, S, Sigurdsson, F, Kure, E, Ikdahl, T, Skovlund, E, Fokstuen, T, Hansen, F, Hofsli, E, Birkemeyer, E, Johnsson, A, Starkhammar, H, Yilmaz, M K, Keldsen, N, Erdal, A B, Dajani, O, Dahl, O & Christoffersen, T 2012, ' Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer : the NORDIC-VII study ', Journal of Clinical Oncology, vol. 30, no. 15, pp. 1755-1762 . https://doi.org/10.1200/JCO.2011.38.0915
Purpose The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6366f01a496b745d50d544c11d83311
http://juuli.fi/Record/0252818812
http://juuli.fi/Record/0252818812
Autor:
Troels K Bergmann, Nina Keldsen, Kristin Skougaard, Kim Brøsen, Henrik Gréen, Charlotte Brasch-Andersen, Mansoor Raza Mirza, Werner Vach, Per Damkier, Jessica Wihl, Carsten Peterson
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 110:199-204
The standard treatment for ovarian cancer in advanced stages is post-surgery treatment with taxane-platin chemotherapy. Despite an initial high response rate, most patients eventually relapse. The dose-limiting toxicities of paclitaxel are neutropeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fa4f43981eacadecb2041bb0dab37b4
https://doi.org/10.1111/j.1742-7843.2011.00802.x
https://doi.org/10.1111/j.1742-7843.2011.00802.x
Autor:
Ib Jarle Christensen, Hans Jørgen Nielsen, Per Pfeiffer, C. Frederiksen, Bengt Glimelius, Svend Erik Nielsen, Åke Berglund, Nina Keldsen, Camilla Qvortrup, Nils Brünner, Benny Vittrup Jensen
Publikováno v:
Frederiksen, C, Qvortrup, C, Christensen, I J, Glimelius, B, Berglund, A, Jensen, B V, Nielsen, S E, Keldsen, N, Nielsen, H J, Brünner, N & Pfeiffer, P 2011, ' Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer ', Annals of Oncology, vol. 22, no. 2, pp. 369-375 . https://doi.org/10.1093/annonc/mdq354
BACKGROUND: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f18850cabb130c211a63a5584e78327
https://doi.org/10.1093/annonc/mdq354
https://doi.org/10.1093/annonc/mdq354
Autor:
René dePont Christensen, Bente Lund, Mansoor Raza Mirza, Anders Mellemgaard, Nina Keldsen, Jacob Christian Lindegaard, Kamma Bertelsen
Publikováno v:
Mirza, M R, Lund, B, Lindegaard, J C, Keldsen, N, Mellemgaard, A, Christensen, R D & Bertelsen, K 2010, ' A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin ', Gynecologic Oncology, vol. 119, no. 1, pp. 26-31 . https://doi.org/10.1016/j.ygyno.2010.06.022
Objective Treatment of epithelial ovarian cancer patients relapsing with a short treatment-free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the activity and feasibility of pegylated liposomal doxorubicin (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27193677fc6d4cb62588c58fde908b3d
https://doi.org/10.1016/j.ygyno.2010.06.022
https://doi.org/10.1016/j.ygyno.2010.06.022
Autor:
Tone Fokstuen, Bengt Glimelius, Svend Erik Nielsen, Camilla Qvortrup, Benny Vittrup Jensen, J. Mejer, Nina Keldsen, Finn Larsen, B. Bjerregaard, Per Pfeiffer
Publikováno v:
Qvortrup, C, Jensen, B V, Fokstuen, T, Nielsen, S E, Keldsen, N, Glimelius, B, Bjerregaard, B, Mejer, J, Larsen, F O & Pfeiffer, P 2009, ' A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer ', Annals of Oncology, vol. 21, no. 1, pp. 87-91 . https://doi.org/10.1093/annonc/mdp272
Udgivelsesdato: 2009-Jul-21 BACKGROUND: Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19dadef648d7f596e95f0099b1dad39c
https://doi.org/10.1093/annonc/mdp272
https://doi.org/10.1093/annonc/mdp272
Autor:
Bernt Ly, K. Thorling, Karl Wesenberg, Trude Grønvold, Jørgen Ellegaard, Erik Hippe, Nina Keldsen, Peter Gimsing, Alv Skarbøvik, Ole Weis Bjerrum, Ingebrigt Talstad, Jon Lamvik, Inger Marie S. Dahl, Ole Gadeberg, Aage Drivsholm, Mogens Mørk Hansen
Publikováno v:
European Journal of Haematology. 51:80-85
One-hundred-and-fifty-one patients with previously untreated multiple myeloma were allocated to treatment with either NOP regimen (mitoxantrone 16 mg/m2 and vincristine 2 mg day 1 and prednisolone 250 mg day 1–4 and 17–20) or M + P regimen (melph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49864e7bb532b7b6a94ccd8fbf2f53ef
https://doi.org/10.1111/j.1600-0609.1993.tb01597.x
https://doi.org/10.1111/j.1600-0609.1993.tb01597.x
Autor:
Lise Balteskard, Åke Berglund, Nina Keldsen, Hans Garmo, R Heikkilä, Kjell Magne Tveit, Per Pfeiffer, Bengt Glimelius, Maria Albertsson, Hans Starkhammar, Per Byström, Halfdan Sorbye
Publikováno v:
Glimelius, B, Sørbye, H, Balteskard, L, Byström, P, Pfeiffer, P, Tveit, K, Heikkilä, R, Keldsen, N, Albertsson, M, Starkhammar, H, Garmo, H & Berglund, A 2008, ' A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer ', Annals of Oncology, vol. 19, no. 5, pp. 909-14 . https://doi.org/10.1093/annonc/mdm588
Udgivelsesdato: 2008-May BACKGROUND: To compare irinotecan with the Nordic 5-fluorouracil (5-FU) and folinic acid (FA) bolus schedule [irinotecan 180 mg/m(2) on day 1, 5-FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2 (FLIRI)] or the Lv5FU2 schedule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61d6dd7bccbe395771704565d3909bb
https://doi.org/10.1093/annonc/mdm588
https://doi.org/10.1093/annonc/mdm588
Autor:
Jan Erik Frödin, Bengt Glimelius, Nina Keldsen, Mogens Kjaer, Anders Jakobsen, Niels Gyldenkerne, Flemming Hansen, Erik Sandberg, Per Pfeiffer
Publikováno v:
University of Southern Denmark
Gyldenkerne, N, Glimelius, B, Frodin, J E, Kjær, M, Pfeiffer, P, Hansen, F, Keldsen, N, Sandberg, E & Jakobsen, A 2004, ' A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer ', Acta Oncologica, vol. 43, no. 3, pp. 276-279 .
Gyldenkerne, N, Glimelius, B, Frodin, J E, Kjær, M, Pfeiffer, P, Hansen, F, Keldsen, N, Sandberg, E & Jakobsen, A 2004, ' A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer ', Acta Oncologica, vol. 43, no. 3, pp. 276-279 .
The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer. Ninety-seven patients were treated with UFT (91 patients 300 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45b88a732433485ff0092be5d82b519
https://doi.org/10.1080/02841860410028655
https://doi.org/10.1080/02841860410028655